Boston Scientific To Participate In Oppenheimer 2015 Healthcare Conference
Get Alerts BSX Hot Sheet
Join SI Premium – FREE
MARLBOROUGH, Mass., Nov. 24, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Oppenheimer 26th Annual Healthcare Conference on December 8, in New York City.
Susie Lisa, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst beginning at approximately 8:35 a.m. ET.
A live webcast of the question-and-answer session will be available on the Investor Relations section of the Boston Scientific website at www.bostonscientific.com/investors. We encourage interested parties to register at least 15 minutes prior to the scheduled start time to ensure a timely connection.
A replay of the webcast will be accessible at www.bostonscientific.com/investors beginning approximately one hour following the completion of the event.
About Boston ScientificBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
CONTACTS |
|
Media: |
Investors: |
Tom Keppeler |
Susie Lisa, CFA |
508-683-6585 (office) |
508- 683-5565 (office) |
Media Relations |
Investor Relations |
Boston Scientific Corporation |
Boston Scientific Corporation |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boston-scientific-to-participate-in-oppenheimer-2015-healthcare-conference-300183376.html
SOURCE Boston Scientific Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guardant Health (GH) Announces FDA Advisory Panel Review of Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
- Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue
- Danske Bank A/S, transactions by persons discharging managerial responsibilities
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!